METTL3 and nonpapillary renal cell carcinoma: Analyses of risk signatures among patients with ccRCC reveal a strong correlation between increased METTL3 expression and adverse pathological characteristics (such as stage, grade, and clinical classifications T, N, and M), along with survival outcomes, which highlights its potential utility in ccRCC prognosis (Gundert et al., 2021).